Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 20/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10170951 | 0.94 | PTGES (0.89) | PTGES | |
| SCHEMBL10169900 | 0.94 | PTGES (0.91) | PTGES | |
| SCHEMBL10170005 | 0.94 | PTGES (0.91) | PTGES | |
| SCHEMBL10170200 | 0.94 | PTGES (0.88) | PTGES | |
| SCHEMBL10170924 | 0.93 | PTGES (1.00) | PTGES | |
| SCHEMBL10170964 | 0.93 | PTGES (0.91) | PTGES | |
| SCHEMBL10169884 | 0.92 | PTGES (0.89) | PTGES | |
| SCHEMBL10170198 | 0.92 | PTGES (0.89) | PTGES | |
| SCHEMBL16152516 | 0.91 | PTGES (0.88) | PTGES | |
| SCHEMBL10170959 | 0.90 | PTGES (0.86) | PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218670-A1 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION | GESYNTA PHARMA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-20190038603-A1 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION | GESYNTA PHARMA AB (SE) | 2019-02-07 | — | — | US | disclosed |
| EP-2606036-B1 | 2-ANILINOBENZIMIDAZOLE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-8759537-B2 | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| WO-2012022793-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218670-A1 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION | PTGIS, PTGIR, PTGER1 | PTGES 4/4885 |
| US-20190038603-A1 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION | PTGIS, PTGIR, PTGER1 | PTGES 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.